Publications in collaboration with researchers from Complexo Hospitalario Universitario da Coruña (17)

2024

  1. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

2023

  1. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  2. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme

    European Journal of Cancer, Vol. 182, pp. 3-14

  3. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study

    Cancer Medicine, Vol. 12, Núm. 6, pp. 6615-6622

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. Venous Thromboembolism In Cancer Patients: “From Evidence to Care”

    Clinical and Applied Thrombosis/Hemostasis, Vol. 28

2021

  1. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain

    BMC Cancer, Vol. 21, Núm. 1

  2. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  3. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

    Scientific Reports, Vol. 11, Núm. 1

  4. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study

    Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267

2019

  1. Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

    Annals of Oncology, Vol. 30, pp. iv42-iv43

  2. Is there any affordable and reliable score in local gastric cancer?

    Annals of Oncology, Vol. 30, pp. iv60

2018

  1. Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience

    Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415

2014

  1. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 3, pp. 451-457

2009

  1. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 2, pp. 379-384

2007

  1. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: A lung cancer Galician group phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 60, Núm. 5, pp. 725-732